The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Indications and Outcomes in Liver Transplantation in Patients With Primary Sclerosing Cholangitis in Norway
Open accessAbstract
BACKGROUND: Primary sclerosing cholangitis (PSC) is 1 of the leading causes of liver transplantation (LTX) in Scandinavia, and an increasing number of PSC patients have been transplanted in Norway during the last 2 decades. This trend is partly attributable to the recently established practice in Norway of offering LTX to PSC patients with cholangiocellular dysplasia. Based on the controversy associated with this practice, we herein aimed to report the main features and outcomes of our LTX program in PSC. METHODS: The primary indication for LTX (quality of life/end-stage liver disease or suspected neoplasia) was retrospectively determined for 222 patients undergoing LTX for PSC or other autoimmune liver diseases (primary biliary cirrhosis/autoimmune hepatitis) with at least 5 years of follow-up. RESULTS: In PSC patients impaired quality of life (43.5%) and end-stage liver disease (38.4%) were the most frequent indications for LTX, whereas suspected neoplasia accounted for 18.1%. The proportion of PSC patients with manifest encephalopathy, variceal bleeding, or ascites declined over time. In patients with suspected neoplasia as the primary indication for LTX (n = 25), neoplasia was confirmed in the explanted liver in 20 patients (80%). Five-year survival rates for PSC patients transplanted between 2001 and 2009 were 91.9% for patients receiving LTX due to impaired quality of life or end-stage liver disease and 83.3% for suspected neoplasia. CONCLUSIONS: The PSC patients are increasingly listed for LTX at an earlier stage of their liver disease. In patients with suspected neoplasia before LTX, 5-year survival was acceptable, despite confirmation of neoplasia in 80% of the liver explants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a wide variation in practice internationally with 17% of people with PSC transplanted for this indication in Norway 245 while less than 5% of people with PSC are listed for this indication in the UK. 1”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [245]
In the citing paper
“Due to the challenges of differentiating early-stage biliary neoplasia from benign bile duct strictures and inflammatory epithelial changes, histology in up to 20% of the liver explants in these individuals may show no signs of neoplasia in real-world settings.245”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [245]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Self-citationBoonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725 · cited 1×
“No medical therapy has so far proven to delay disease progression,(2) andmore than half of the patients will face an endpoint of liver transplantation (LTX) or death within 12 to 21 years after diagnosis.(3,4) The high lifetime cumulative risk of developing cholangiocarcinoma (10-15%) in PSC further complicates the ti…”
BackgroundHepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717 · cited 1×
“The high lifetime cumulative risk of developing cholangiocarcinoma (10-15%) in PSC further complicates the timing of LTX and accounts for death in almost half of the cases.(5) The etiology of PSC is unknown,(6) but like in primary biliary cirrhosis (PBC)”
BackgroundDarwish Murad, S., Kim, W. R., Harnois, D. M., Douglas, D. D., Burton, J., Kulik, L. M., Botha, J. F., Mezrich, J. D., Chapman, W. C., Schwartz, J. J., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.008 · Cited by 597
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 592
Self-citationDe Vreede, I., Steers, J. L., Burch, P. A., Rosen, C. B., Gunderson, L. L., Haddock, M. G., Burgart, L., & Gores, G. J. (2000) · Liver Transplantation · doi:10.1053/lv.2000.6143 · Cited by 395 · cited 1×
“3% for patients with a primary indication of suspected neoplasia is good and exceeding results after LTX for manifest cholangiocarcinoma after neoadjuvant chemoirradiation and brachytherapy.(29) Manifest cholangiocarcinoma is generally associated with poor post-LTX survival and a contraindication for LTX,(30) also in…”
Brandsæter, B., Isoniemi, H., Broomé, U., Olausson, M., Bäckman, L., Hansen, B., Schrumpf, E., Oksanen, A., Ericzon, B.-G., Höckerstedt, K., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.01.002 · Cited by 201
Self-citationBangarulingam, S. Y., Bjornsson, E., Enders, F., Barr Fritcher, E. G., Gores, G., Halling, K. C., & Lindor, K. D. (2010) · Hepatology · doi:10.1002/hep.23277 · Cited by 173
Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis
Boberg, K. M., Jebsen, P., Clausen, O. P., Foss, A., Aabakken, L., & Schrumpf, E. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.010 · Cited by 159 · cited 1×
“The most commonly used method for early cholangiocarcinoma detection in PSC is assessment of brush cytology specimens, obtained at endoscopic retrograde cholangiography by brushing in a region of a suspicious stricture.(11) No prospectively validated screening algorithm for early cholangiocarcinoma detection in PSC ha…”
MethodSelf-citationWeismüller, T. J., Fikatas, P., Schmidt, J., Barreiros, A. P., Otto, G., Beckebaum, S., Paul, A., Scherer, M. N., Schmidt, H., Schlitt, H. J., et al. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01161.x · Cited by 146 · cited 1×
“However, high MELD scores are also associated with increased perioperative and postoperative mortality, and a decline in survival after clinical implementation of the MELD criteria has been suggested by some authors.(21) We observed favorable survival rates for patients transplanted on the basis of impaired quality of…”
Background
Research works printed but not linked: 2
- Taniguchi, 2012, Liver transplantation in the MELD eraanalysis of the OPTNUNOS registry., Clin Transpl, 41-, 65
- Wiesner, 1996, Liver transplantation for primary sclerosing cholangitis: impact of risk factors on outcome., Liver Transpl Surg, 2, 99
Cited by
Primary sclerosing cholangitis – a comprehensive review
Karlsen, T. H., Folseraas, T., Thorburn, D., & Vesterhus, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.022 · Cited by 868
Self-citationEASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Self-citationChapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317993 · Cited by 284
Holmer, M., Melum, E., Isoniemi, H., Ericzon, B., Castedal, M., Nordin, A. J., Schultz, N. A., Rasmussen, A., Line, P., Stal, P. I., et al. (2018) · Liver International · doi:10.1111/liv.13751 · Cited by 72
Self-citationCarbone, M., Penna, A. D., Mazzarelli, C., Martin, E. D., Villard, C., Bergquist, A. M., Line, P., Neuberger, J., Al-Shakhshir, S., Trivedi, P. J., et al. (2023) · Transplant International · doi:10.3389/ti.2023.11729 · Cited by 61
“In some centers, high-grade biliary dysplasia and early cholangiocarcinoma are also accepted as indications [2].”
BackgroundSelf-citation
Metadata
- Authors
- Andersen, I. M., Fosby, B., Boberg, K. M., Clausen, O. P. F., Jebsen, P., Melum, E., Line, P. D., Foss, A., Schrumpf, E., & Karlsen, T. H.
- Affiliations
- Oslo University Hospital (NO)
- Corresponding author
- Fosby, Bjarte
- Venue
- Transplantation Direct
- Published
- 2015-10
- Volume
- 1
- Issue
- 9
- Pages
- e39
- ISSN
- 2373-8731 (ISSN-L)
- PMC
- PMC4946487
- OpenAlex
- W2521381657
- Cited by
- 45
- References
- 33
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 3
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Transplantation Direct (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- primary sclerosing cholangitis, liver transplantation, transplant indications, end-stage liver disease, quality of life, post-transplant survival, autoimmune liver disease, primary biliary cirrhosis, autoimmune hepatitis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Indications and Outcomes in Liver Transplantation in Patients With Primary Sclerosing Cholangitis in Norway. https://app.cochat.ai/papers/10.1097/txd.0000000000000548
- The paper
- Andersen, I. M., Fosby, B., Boberg, K. M., Clausen, O. P. F., Jebsen, P., Melum, E., Line, P. D., Foss, A., Schrumpf, E., & Karlsen, T. H. (2015). Indications and Outcomes in Liver Transplantation in Patients With Primary Sclerosing Cholangitis in Norway. Transplantation Direct. https://doi.org/10.1097/txd.0000000000000548
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
